But in an unexpected twist, the company added the development and manufacturing of stem-cell-therapy products to its portfolio, which gave them the idea of creating original cell-culture media.

Translation of human pluripotent stem cells into cell therapies will require the development of standardized tests for product consistency, stability, tumorigenicity, toxicity and immunogenicity.

Travel to the Bahamas and—for the meager sum of $16,500—you could have stem cells injected into your joints. The in-vogue-but-uproven treatments are popular with celebrities and wealthy ...

Most Australians now consider their pets to be on the same level as their spouses or children, and now they can access ...

The Global Stem Cell Therapy Market is projected to reach USD 18.9 billion in 2024 which is further anticipated to reach USD 54.7 billion by 2033 at a CAGR of 12.6%. The global stem cell therapy ...

Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for ...

prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone on January 23, 2007 and is ...